Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX in first-line metastatic or recurrent nasopharyngeal carcinoma
NCT00436800Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2005
- Primary completion
- Oct 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in nasopharyngeal carcinoma (NPC), sponsored by Sanofi. Started Mar 2005; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00436800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00436800.